Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Sham Injection Clear all
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 5, 2026, 10:54 PM EDT
Not listed Not applicable Interventional

Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy

NCT02346357
View directory record Official record
Conditions
Pain
Interventions
Obturator Nerve Block, Ropivacaine, Placebo Saline
Procedure · Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 5, 2026, 10:54 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension

NCT04454203
View directory record Official record
Conditions
Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions
Mepivacaine, Saline, Perifemoral Injection of Local Anesthetic
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bone Marrow Concentrate Intradiscal Injection for Chronic Discogenic Low Back Pain

NCT03340818
View directory record Official record
Conditions
Discogenic Pain
Interventions
Bone Marrow Concentrate, Placebo
Other
Lead sponsor
APM Spine and Sports Physicians
Other
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
View directory record Official record
Conditions
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions
LFG316, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 5, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

NCT02302079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Macular Edema
Interventions
ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection
Drug · Other
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01713959
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System treatment, Sham treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00876863
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery
Drug · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
55 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Not applicable Interventional Results available

Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia

NCT01771952
View directory record Official record
Conditions
Chondromalacia Patella, Patellofemoral Pain Syndrome
Interventions
Synvisc-One™, Sham Treatment
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
15 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 5, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 5, 2026, 10:54 PM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Results available

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

NCT00203203
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Intramyocardial Injection of stem cells via NOGA Mapping, Control, then Stem Cell Therapy
Device · Other
Lead sponsor
Texas Heart Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 5, 2026, 10:54 PM EDT
Active, not recruiting Phase 3 Interventional

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

NCT05516992
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
SB-01 For Injection, Sham Needle
Drug
Lead sponsor
Spine BioPharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 5, 2026, 10:54 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty

NCT01758497
View directory record Official record
Conditions
Pain Disorder, Sensory Deficit
Interventions
Fascia Iliaca compartment block
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Results available

Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction

NCT05048667
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Shock Wave therapy (SWT), Platelet Rich Plasma (PRP), Sham SWT, Placebo Saline
Device · Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

NCT03626636
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Risuteganib, Sham
Drug · Other
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 5, 2026, 10:54 PM EDT
Not yet recruiting Phase 1 Interventional

Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery

NCT07803250
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
BPC-157, Sham (No Treatment)
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Semaglutide on Nicotine Intake

NCT05530577
View directory record Official record
Conditions
Tobacco Use Disorder, Nicotine Addiction
Interventions
Semaglutide, Sham/placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 5, 2026, 10:54 PM EDT
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 10:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control

NCT01279447
View directory record Official record
Conditions
Internal Derangement of Knee
Interventions
0.25% Bupivacaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 5, 2026, 10:54 PM EDT